Format

Send to

Choose Destination
See comment in PubMed Commons below
Psychopharmacology (Berl). 2007 May;191(4):1023-6. Epub 2007 Feb 23.

Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up.

Author information

  • 1Clinic for Psychosomatic Medicine and Psychotherapy, Medical University of Graz, 8990, Bad Aussee, Austria. m.nickel@klinik-badaussee.at

Abstract

RATIONALE:

Only one controlled trial is known that employed aripiprazole for patients with borderline personality disorder (BPD). This 8-week trial found significant changes on most scales of the symptom checklist (SCL-90-R), Hamilton depression rating scale (HDRS), Hamilton anxiety rating scale (HARS), and on all scales of the state-trait anger expression inventory (STAXI). OBJECTIVES, MATERIALS, AND METHODS: To assess the long-term effectiveness of aripiprazole with multifaceted borderline symptomatology, this 18-month follow-up observation with biannual testing was carried out with the same patients from the previous trial (treated with 15-mg aripiprazole daily, n = 26, 21 female and 5 male patients; previous placebo group, n = 26, 22 female and 4 male patients).

RESULTS:

According to the intent-to-treat principle, significant changes on all scales of the SCL-90-R, HDRS, HARS, and STAXI were observed in the aripiprazole-treated subjects after 18 months.

CONCLUSION:

Aripiprazole appears to be an effective and relatively safe agent in the long-term treatment of patients with BPD.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk